Literature DB >> 15570496

[Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication].

Oliver Strasser1, Max Schmauss, Thomas Messer.   

Abstract

OBJECTIVE: This research examines how successful recommended longterm medical treatment of schizophrenic patients is following their discharge from inpatient treatment by evaluating the yearly rehospitalization rates.
METHODS: The sample consisted of 76 patients with schizophrenia who were admitted for the first time into Bezirkskrankenhaus Augsburg within a year. The recommended long-term medical treatment with conventional or atypical antipsychotics of patients after discharge and the one year rehospitalization rate depending on the medical treatment at time of discharge were examined.
RESULTS: After discharge from hospital more than 50 % of the observed patients were treated with atypical antipsychotics like olanzapine, risperidone or amisupride. Only 9 % were discharged with conventional neuroleptics. 38 % of the 76 observed patients had to be readmitted.
CONCLUSIONS: This research shows that the beneficial properties of modern atypical antipsychotics are less favourable on a lower rehospitalization rate than expected.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570496     DOI: 10.1055/s-2004-828501

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  4 in total

Review 1.  Adverse effects of atypical antipsychotics in the elderly: a review.

Authors:  Pietro Gareri; Pasquale De Fazio; Salvatore De Fazio; Norma Marigliano; Guido Ferreri Ibbadu; Giovambattista De Sarro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study.

Authors:  Miroslav Herceg; Vlado Jukić; Domagoj Vidović; Viktorija Erdeljić; Ivan Celić; Oliver Kozumplik; Dario Bagarić; Maja Silobrcić Radić
Journal:  Croat Med J       Date:  2008-04       Impact factor: 1.351

3.  Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada).

Authors:  Soma Ganesan; Mario McKenna; Ric M Procyshyn; Sheldon Zipursky
Journal:  Curr Ther Res Clin Exp       Date:  2007-11

4.  Acceptance and Commitment Therapy for Inpatients with Psychosis (the REACH Study): Protocol for Treatment Development and Pilot Testing.

Authors:  Brandon A Gaudiano; Carter H Davis; Gary Epstein-Lubow; Jennifer E Johnson; Kim T Mueser; Ivan W Miller
Journal:  Healthcare (Basel)       Date:  2017-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.